QUOTE AND NEWS
Jutia Group  Aug 21  Comment 
[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on...
FierceBiotech  Aug 21  Comment 
Following fast on the heels of a rival development team at Novartis, Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab compared to Pfizer's Enbrel in a head-to-head study. And Lilly says...
Wall Street Journal  Aug 21  Comment 
Eli Lilly said its psoriasis treatment ixekizumab showed positive results in phase 3 studies, preparing the way for its submission to regulatory authorities.
The Economic Times  Aug 21  Comment 
The marketing approval for Gemcitabine will help the company further strengthen its oncology portfolio and improve its presence in this space.
Motley Fool  Aug 20  Comment 
At a critical time for the company, Eli Lilly's management has laid out its plans to return to growth and gave us a good look at what the future holds.
MedPage Today  Aug 20  Comment 
(MedPage Today) -- The FDA has tentatively approved Eli Lilly's "biosimilar" insulin glargine (Basaglar), but it won't be on the market until the company resolves patent litigation with Sanofi.
newratings.com  Aug 19  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co (LLY) said Monday the U.S. Food and Drug Administration granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes...
StreetInsider.com  Aug 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FDA+Awards+Tentative+Approval+for+Lilly%2C+Boehringer+Ingelheim%27s+Basaglar+%28LLY%29/9764028.html for the full story.
Jutia Group  Aug 18  Comment 
[PR Newswire] - Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime...
SeekingAlpha  Aug 18  Comment 
By Balanced Investing: In the season of earnings release, Eli Lilly and Company (NYSE:LLY) has also joined the list by announcing its second quarter results. The company's performance can be assessed by analyzing the patents that it currently...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki